Total Wealth Planning & Management Inc. Takes $390,000 Position in GSK plc (NYSE:GSK)

Total Wealth Planning & Management Inc. bought a new position in GSK plc (NYSE:GSK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,525 shares of the pharmaceutical company's stock, valued at approximately $390,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of GSK during the fourth quarter valued at approximately $13,730,000. Brucke Financial Inc. bought a new position in GSK in the 4th quarter worth about $465,000. Yoffe Investment Management LLC purchased a new stake in shares of GSK during the fourth quarter valued at approximately $462,000. Forum Financial Management LP boosted its stake in GSK by 167.9% during the 4th quarter. Forum Financial Management LP now owns 13,397 shares of the pharmaceutical company's stock valued at $453,000 after purchasing an additional 8,396 shares during the last quarter. Finally, Michels Family Financial LLC bought a new stake in GSK in the 4th quarter worth about $377,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

GSK has been the topic of several recent research reports. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Finally, BNP Paribas began coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Price Performance

Shares of NYSE:GSK traded down $0.22 during trading on Wednesday, reaching $39.22. The stock had a trading volume of 4,220,823 shares, compared to its average volume of 4,837,203. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.01. The stock has a market cap of $80.92 billion, a PE ratio of 24.67, a PEG ratio of 1.12 and a beta of 0.51. The business has a fifty day moving average price of $37.26 and a 200-day moving average price of $36.08. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter last year, the firm earned $0.43 EPS. The business's revenue was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.30%. GSK's payout ratio is currently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.